Gene or Genome
X4 Pharmaceuticals Restructures to Advance Mavorixafor for Chronic Neutropenia and Optimize XOLREMDI Promotion
X4 Pharmaceuticals, mavorixafor, XOLREMDI, CXCR4 antagonist, WHIM syndrome, chronic neutropenia, workforce reduction, strategic restructuring
Kura Oncology’s Ziftomenib Achieves Phase 2 Success in AML, Paving Way for Dual-Track Phase 3 Program
Ziftomenib, Acute Myeloid Leukemia (AML), NPM1 mutation, KMT2A rearrangement, Phase 3 trials, KOMET-001, KOMET-017, Menin inhibitor, Breakthrough Therapy Designation
NFL Legend Jerome Bettis Joins CDC Foundation’s “Live to the Beat” Campaign to Tackle Heart Health in Black Community
Jerome Bettis, CDC Foundation, Live to the Beat, cardiovascular disease, Black community, hypertension, heart health, NFL
Pharmaceutical Industry Warns of Drug Shortages and Price Hikes Due to Trump’s New Tariffs
Trump tariffs, drug shortages, price increases, pharmaceutical industry, trade groups, supply chain disruption, generic drugs, active pharmaceutical ingredients (APIs)
Trump Imposes New Tariffs on Canada, Mexico, and China; Medical Industry Seeks Exemptions
Trump tariffs, Canada, Mexico, China, medical technology exemptions, trade policy, national security, fentanyl crisis, illegal immigration
Zentalis Pharmaceuticals Cuts Workforce by 40% to Advance WEE1 Inhibitor to Registrational Trial
Zentalis Pharmaceuticals, layoffs, WEE1 inhibitor, azenosertib, clinical trials, cancer treatment, biotech industry
Leap Therapeutics’ Stock Plummets Following Disappointing DKK1 Antibody Results in Gastric Cancer Trials
Leap Therapeutics, DKK1 Antibody, Gastric Cancer, Clinical Trials, Stock Performance
Trump 2.0: RFK Confirmation Hearings and Ongoing Clinical Trials Amidst Administrative Changes
Trump 2.0, RFK Confirmation Hearings, Clinical Trials, NIH Grant Reviews, US-India Partnership, Second Term Policies
Emerging Competitors in Achondroplasia Treatment: BioMarin’s Dominance Faces New Challenges
Achondroplasia, BioMarin, Voxzogo, BridgeBio, infigratinib, TransCon CNP, RBM-007, skeletal disorders, dwarfism, genetic bone disorders.
Leo Pharma Acquires EU Rights to Loqtorzi, Boosting Marketing Efforts for PD-1 Inhibitor
Loqtorzi, PD-1 Inhibitor, Nasopharyngeal Carcinoma, EU Rights, Leo Pharma, Junshi Biosciences, Marketing Efforts